Biotech | March 25, 2026
Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
Capital infusion to accelerate Earendil’s R&D platform
Capital infusion to accelerate Earendil’s R&D platform
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
This transaction fundamentally strengthens Scinai's CDMO platform
Iberdomide has the potential to be the first approved CELMoD agent
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
Subscribe To Our Newsletter & Stay Updated
